Table 1.

Outcomes for combined androgen-deprivation therapy and radiotherapy in high-risk disease.

Study	PSA failure	Distant metastasis	Prostate cancer death	Overall survival
Pilepich et al.4	65% at 10 years	35% at 10 years	23% at 10 years	43% at 10 years
Horwitz et al.3	52% at 10 years	23% at 10 years	11% at 10 years	52% at 10 years
Pilepich et al.2	31% at 10 years (PSA < 1.5 ng/mL)	24% at 10 years	16% at 10 years	49% at 10 years
Bolla et al.1	24% at 5 years	10% at 5 years	6% at 5 years	78% at 5 years

PSA = prostate-specific antigen.